TheraSolve Announces US Patent Issuance for MemoPatch®
15 September 2015, Diepenbeek, Belgium – TheraSolve NV, a medication adherence innovator, announced today patent issuance from the United States Patent and Trademark Office for its innovative MemoPatch® reminder technology.
Specifically designed to support patients with treatment compliance, MemoPatch® is a self-adhesive dermal patch that gives patients an automated, discreet yet clear stimulus on the skin when the next dose of medication is needed. MemoPatch® is currently patent protected in the US, EU, Japan, China and India.
Wim De Geest, CEO and co-founder of TheraSolve stated: “The patents we have obtained to date validate MemoPatch® as a unique product that can help address compliance issues across myriad, if not all, therapeutic areas. This United States Patent allows protected MemoPatch® market entry to a substantial new market segment. We aim to achieve marketing approval in the EU in 2016, FDA approval will be achieved subsequently. In the near-term, we will initiate studies with MemoPatch® in specific clinical settings to demonstrate the effect of this device on medication adherence.”